What is National Health Investors's earnings per share (EPS)?

National Health Investors (NHI) reported diluted earnings per share of $3.02 for fiscal year 2025. This represents a -3.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

National Health Investors Financials

NHI

FY2025 annual

Revenue $375.6M +12.1% YoY

Net Income $142.2M +3.0% YoY

EPS (Diluted) $3.02 -3.5% YoY

Free Cash Flow -$57.5M -215.3% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

National Health Investors (NHI) reported $375.6M in revenue for fiscal year 2025, up 12.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NHI FY2025 2026-05-04

Cash-generative operations are being masked by a sharp reinvestment cycle, making free cash flow look weaker than underlying earnings power.

Across FY2023-FY2025, net income stayed roughly flat while operating cash flow improved, indicating the existing asset base kept producing cash even without a profit step-up. The swing came from capital deployment: capex rose from $49.6M to $294.0M, turning free cash flow from $134.9M to -$57.5M and shifting the cash story from harvest to reinvestment.

FY2025 operating cash flow of $236.6M was far above net income of $142.2M. With depreciation and amortization at $80.9M, reported profit is a conservative read on the cash this asset base generates before new investment decisions.

Dividends paid of $169.7M exceeded both net income and free cash flow in FY2025, which looks harsher than it is because free cash flow was depressed by heavy reinvestment. The better operating lens is cash generation before expansion spending: operating cash flow reached $236.6M, so the payout shortfall was tied to investment pace rather than weak recurring cash production.

Financial Health Signals

Financial Health Score 33/100

Scored as: REITs peer group

Scored against REITs for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of National Health Investors's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

FFO Margin

FFO Growth

Leverage

Not available for National Health Investors, and counted as zero in the overall score.

Interest Cov.

Not available for National Health Investors, and counted as zero in the overall score.

AFFO Margin

Dividend Cov.

Piotroski F-Score Partial

4/6

National Health Investors passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.66x

For every $1 of reported earnings, National Health Investors generates $1.66 in operating cash flow ($236.6M OCF vs $142.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$375.6M

YoY+12.1%

5Y CAGR+2.5%

10Y CAGR+5.1%

National Health Investors generated $375.6M in revenue in fiscal year 2025. This represents an increase of 12.1% from the prior year.

Net Income

$142.2M

YoY+3.0%

5Y CAGR-5.1%

10Y CAGR-0.5%

National Health Investors reported $142.2M in net income in fiscal year 2025. This represents an increase of 3.0% from the prior year.

EPS (Diluted)

$3.02

YoY-3.5%

5Y CAGR-6.1%

10Y CAGR-2.6%

National Health Investors earned $3.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 3.5% from the prior year.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$57.5M

YoY-215.3%

National Health Investors recorded an outflow of $57.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 215.3% from the prior year.

Cash & Debt

$19.6M

YoY-19.2%

5Y CAGR-14.7%

10Y CAGR+4.1%

National Health Investors held $19.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Dividends Per Share

$3.64

YoY+1.1%

5Y CAGR-3.8%

10Y CAGR+0.7%

National Health Investors paid $3.64 per share in dividends in fiscal year 2025. This represents an increase of 1.1% from the prior year.

Shares Outstanding

48M

YoY+5.7%

5Y CAGR+1.3%

10Y CAGR+2.3%

National Health Investors had 48M shares outstanding in fiscal year 2025. This represents an increase of 5.7% from the prior year.

Margins & Returns

Net Margin

37.9%

YoY-3.3pp

5Y CAGR-17.8pp

10Y CAGR-27.2pp

National Health Investors's net profit margin was 37.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.3 percentage points from the prior year.

Return on Equity

9.3%

YoY-0.8pp

5Y CAGR-2.9pp

10Y CAGR-3.8pp

National Health Investors's ROE was 9.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.8 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Capital Allocation

Capital Expenditures

$294.0M

YoY+86.2%

5Y CAGR+20.3%

10Y CAGR+9.0%

National Health Investors invested $294.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 86.2% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

Share Buybacks

Not reported for fiscal year 2025.

NHI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NHI annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$432.1M	$375.6M+12.1%	$335.2M+4.8%	$319.8M+15.0%	$278.2M-6.9%	$298.7M-10.2%	$332.8M+4.6%	$318.1M+8.0%	$294.6M+5.7%	$278.7M+12.2%	$248.5M+8.5%	$228.9M+29.0%	$177.5M+50.7%	$117.8M+26.3%	$93.3M+11.4%	$83.7M
SG&A Expenses	$30.6M	$26.9M+29.6%	$20.7M+7.4%	$19.3M-15.2%	$22.8M+23.5%	$18.4M+38.5%	$13.3M-0.7%	$13.4M+6.8%	$12.5M+2.7%	$12.2M+25.0%	$9.8M-7.1%	$10.5M+15.5%	$9.1M-1.6%	$9.3M+18.7%	$7.8M+2.8%	$7.6M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$150.3M+45.9%	$103.1M+29.6%	$79.5M+9.1%	$72.8M+4.3%	$69.8M
Interest Expense	$58.9M	$57.4M-4.2%	$59.9M+3.0%	$58.2M+29.5%	$44.9M-11.6%	$50.8M-3.9%	$52.9M-6.1%	$56.3M+14.8%	$49.1M+5.9%	$46.3M+7.5%	$43.1M+14.6%	$37.6M+42.7%	$26.4M+185.8%	$9.2M+164.3%	$3.5M-9.3%	$3.8M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$138K+11.3%	$124K-85.5%	$854K+246.5%	-$583K-594.1%	$118K0.0%	$118K-55.8%	$267K+178.1%	$96K
Net Income	$166.8M	$142.2M+3.0%	$138.0M+1.7%	$135.7M+104.3%	$66.4M-40.6%	$111.8M-39.6%	$185.1M+15.4%	$160.5M+4.0%	$154.3M-3.2%	$159.4M+5.2%	$151.5M+1.8%	$148.9M+46.5%	$101.6M-4.3%	$106.2M+17.0%	$90.7M+11.8%	$81.1M
EPS (Diluted)	—	$3.02-3.5%	$3.130.0%	$3.13+111.5%	$1.48-39.3%	$2.44-41.1%	$4.14+12.8%	$3.670.0%	$3.67-5.2%	$3.870.0%	$3.87-2.0%	$3.95+29.9%	$3.04-18.7%	$3.74+14.7%	$3.26+11.6%	$2.92

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$121.3M+5.4%	$115.1M+8.8%	$105.8M+17.8%	$89.8M-0.9%	$90.7M+1.5%	$89.3M+4.1%	$85.8M+3.4%	$82.9M
SG&A Expenses	$8.8M+12.4%	$7.9M+3.3%	$7.6M+20.5%	$6.3M+3.0%	$6.1M-10.3%	$6.8M+26.1%	$5.4M+12.6%	$4.8M
Interest Expense	$15.8M+5.1%	$15.0M+5.4%	$14.3M+3.6%	$13.8M-8.2%	$15.0M+4.6%	$14.3M-5.9%	$15.2M+2.0%	$14.9M
Income Tax	$732K	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	$55.7M+38.8%	$40.1M+5.1%	$38.2M+16.1%	$32.9M-11.2%	$37.0M+8.3%	$34.2M-21.0%	$43.2M+51.5%	$28.5M
EPS (Diluted)	$1.15+40.2%	$0.82	N/A	$0.69-12.7%	$0.79+6.8%	$0.74	N/A	$0.65

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

NHI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NHI annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$2.8B+7.0%	$2.6B+5.1%	$2.5B-0.8%	$2.5B-11.7%	$2.8B-9.0%	$3.1B+2.6%	$3.0B+10.6%	$2.8B+8.0%	$2.5B+5.9%	$2.4B+12.7%	$2.1B+7.6%	$2.0B+36.2%	$1.5B+106.2%	$706.0M+21.8%	$579.6M
Cash & Equivalents	$19.6M-19.2%	$24.3M+8.7%	$22.3M+15.8%	$19.3M-48.4%	$37.4M-13.7%	$43.3M+731.1%	$5.2M+11.9%	$4.7M+52.1%	$3.1M-36.6%	$4.8M-63.1%	$13.1M+323.5%	$3.1M-72.7%	$11.3M+23.3%	$9.2M-42.3%	$15.9M
Accounts Receivable	N/A	N/A	N/A	$3.6M+12.8%	$3.2M+23.7%	$2.6M-19.2%	$3.2M-49.7%	$6.4M+162.7%	$2.4M-73.6%	$9.2M+182.6%	$3.3M-14.6%	$3.8M+52.6%	$2.5M+37.9%	$1.8M+46.8%	$1.2M
Total Liabilities	$1.3B+2.3%	$1.2B+1.2%	$1.2B-0.3%	$1.2B-7.9%	$1.3B-17.3%	$1.6B+3.5%	$1.5B+13.5%	$1.4B+11.2%	$1.2B+2.5%	$1.2B+20.5%	$990.8M+6.2%	$933.0M+37.5%	$678.7M+185.2%	$237.9M+74.9%	$136.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.1B	N/A	N/A	$80.1M	$0	N/A
Total Equity	$1.5B+11.3%	$1.4B+9.0%	$1.3B-1.3%	$1.3B-15.7%	$1.5B-0.3%	$1.5B+1.0%	$1.5B+7.8%	$1.4B+5.1%	$1.3B+9.3%	$1.2B+6.7%	$1.1B+9.0%	$1.0B+35.7%	$766.5M+67.7%	$457.2M+3.1%	$443.5M
Retained Earnings	$2.7B+5.5%	$2.6B+5.6%	$2.5B+5.8%	$2.3B	N/A	N/A	N/A	N/A	N/A	$29.9M+50.4%	$19.9M	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$3.0B+2.6%	$2.9B+3.3%	$2.8B+4.0%	$2.7B-0.2%	$2.7B-3.1%	$2.8B+6.4%	$2.6B+6.3%	$2.5B
Cash & Equivalents	$30.4M+21.8%	$24.9M+27.1%	$19.6M-76.0%	$81.6M+337.9%	$18.6M-86.2%	$135.0M+455.8%	$24.3M+56.2%	$15.6M
Total Liabilities	$1.4B+1.3%	$1.4B+8.0%	$1.3B+5.5%	$1.2B-0.6%	$1.2B-10.4%	$1.3B+8.9%	$1.2B+1.4%	$1.2B
Total Equity	$1.6B+3.7%	$1.5B-0.4%	$1.5B+2.7%	$1.5B+0.1%	$1.5B+3.7%	$1.4B+4.4%	$1.4B+11.2%	$1.2B
Retained Earnings	$2.8B+2.0%	$2.8B+1.5%	$2.7B+1.4%	$2.7B+1.2%	$2.7B+1.4%	$2.6B+1.3%	$2.6B+1.7%	$2.6B

Not reported in any period shown, so not listed: Current Assets, Inventory, Goodwill, Current Liabilities.

NHI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NHI annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$248.7M	$236.6M+13.9%	$207.8M+12.6%	$184.4M-0.5%	$185.3M-12.1%	$210.9M-9.2%	$232.1M-3.7%	$241.0M+15.9%	$207.9M+4.9%	$198.1M+12.1%	$176.6M+7.4%	$164.4M+30.3%	$126.1M+21.1%	$104.2M+20.8%	$86.3M+12.2%	$76.9M
Capital Expenditures	N/A	$294.0M+86.2%	$157.9M+218.7%	$49.6M+350.8%	$11.0M-78.2%	$50.3M-56.9%	$116.7M-50.8%	$237.2M+60.6%	$147.6M-16.0%	$175.8M-55.5%	$394.7M+218.0%	$124.1M-76.7%	$533.2M-18.6%	$654.7M+491.9%	$110.6M+45.9%	$75.8M
Free Cash Flow	N/A	-$57.5M-215.3%	$49.8M-63.1%	$134.9M-22.6%	$174.3M+8.6%	$160.5M+39.1%	$115.4M+2962.5%	$3.8M-93.7%	$60.2M+170.0%	$22.3M+110.2%	-$218.1M-641.0%	$40.3M+109.9%	-$407.0M+26.1%	-$550.5M-2162.1%	-$24.3M-2422.0%	$1.0M
Investing Cash Flow	-$292.7M	-$269.1M-40.0%	-$192.3M-1553.6%	-$11.6M-105.9%	$197.9M+6.8%	$185.3M+306.5%	-$89.7M+73.8%	-$342.5M-36.8%	-$250.3M-52.8%	-$163.8M+50.3%	-$329.8M-141.9%	-$136.3M+74.8%	-$540.3M+13.7%	-$625.8M-527.0%	-$99.8M-79.9%	-$55.5M
Financing Cash Flow	$75.1M	$25.7M+289.5%	-$13.6M+92.0%	-$169.7M+57.7%	-$401.3M+0.4%	-$403.0M-260.6%	-$111.8M-204.1%	$107.3M+142.5%	$44.3M+226.3%	-$35.1M-124.3%	$144.2M+896.5%	-$18.1M-104.5%	$406.1M-22.5%	$523.8M+7568.7%	$6.8M+183.7%	-$8.2M
Dividends Paid	$175.6M	$169.7M+8.4%	$156.5M+0.2%	$156.2M-3.4%	$161.8M-11.6%	$182.9M-6.0%	$194.6M+8.3%	$179.7M+8.7%	$165.4M+8.1%	$153.0M+10.7%	$138.3M+10.9%	$124.7M+23.9%	$100.7M+18.2%	$85.1M+7.9%	$78.9M+16.2%	$67.9M
Share Buybacks	N/A	N/A	$0	$0-100.0%	$152.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$65.0M+21.6%	$53.4M-21.1%	$67.7M+8.3%	$62.5M+4.5%	$59.8M+28.7%	$46.5M-19.3%	$57.6M+18.4%	$48.6M
Capital Expenditures	N/A	$109.4M-23.6%	$143.3M	N/A	N/A	$85.2M-23.2%	$110.8M	N/A
Free Cash Flow	N/A	-$56.0M+25.9%	-$75.6M	N/A	N/A	-$38.7M+27.4%	-$53.3M	N/A
Investing Cash Flow	-$43.4M+58.2%	-$103.9M+44.5%	-$187.0M-548.9%	$41.7M+186.2%	-$48.3M+36.0%	-$75.5M+53.2%	-$161.2M-10154.4%	-$1.6M
Financing Cash Flow	$3.9M-93.0%	$55.8M-2.7%	$57.3M+236.7%	-$41.9M+67.6%	-$129.5M-192.6%	$139.8M+24.4%	$112.4M+343.2%	-$46.2M
Dividends Paid	$44.6M+0.3%	$44.4M+1.4%	$43.8M+2.6%	$42.7M+1.7%	$42.0M+2.2%	$41.1M+4.7%	$39.3M+0.4%	$39.1M

NHI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

NHI annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	65.6%+7.6pp	58.1%-9.4pp	67.5%-10.6pp	78.0%-5.3pp	83.4%
Net Margin	37.9%-3.3pp	41.2%-1.2pp	42.4%+18.5pp	23.9%-13.6pp	37.4%-18.2pp	55.6%+5.2pp	50.4%-1.9pp	52.4%-4.8pp	57.2%-3.8pp	61.0%-4.0pp	65.0%+7.8pp	57.2%-32.9pp	90.1%-7.1pp	97.2%+0.3pp	96.9%
Return on Equity	9.3%-0.8pp	10.1%-0.7pp	10.8%+5.6pp	5.2%-2.2pp	7.4%-4.8pp	12.2%+1.5pp	10.7%-0.4pp	11.1%-0.9pp	12.0%-0.5pp	12.5%-0.6pp	13.1%+3.4pp	9.8%-4.1pp	13.9%-6.0pp	19.9%+1.6pp	18.3%
Return on Assets	5.1%-0.2pp	5.3%-0.2pp	5.5%+2.8pp	2.6%-1.3pp	3.9%-2.0pp	5.9%+0.7pp	5.3%-0.3pp	5.6%-0.7pp	6.3%0.0pp	6.3%-0.7pp	7.0%+1.9pp	5.1%-2.2pp	7.3%-5.6pp	12.8%-1.2pp	14.0%
Debt-to-Equity	0.83-0.1x	0.90-0.1x	0.970.0x	0.96+0.1x	0.88-0.2x	1.060.0x	1.03+0.1x	0.98+0.1x	0.930.0x	0.94+0.1x	0.870.0x	0.90+0.8x	0.10+0.1x	0.00-0.3x	0.31
FCF Margin	-15.3%-30.2pp	14.9%-27.3pp	42.2%-20.5pp	62.7%+8.9pp	53.7%+19.1pp	34.7%+33.5pp	1.2%-19.3pp	20.4%+12.4pp	8.0%+95.8pp	-87.8%-105.4pp	17.6%	-229.3%	-467.2%	-26.1%-27.3pp	1.3%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Net Margin	45.9%+11.1pp	34.8%-1.2pp	36.1%-0.5pp	36.6%-4.2pp	40.8%+2.5pp	38.3%-12.2pp	50.4%+16.0pp	34.4%
Return on Equity	3.5%+0.9pp	2.6%+0.1pp	2.5%+0.3pp	2.2%-0.3pp	2.5%+0.1pp	2.4%-0.8pp	3.2%+0.8pp	2.3%
Return on Assets	1.9%+0.5pp	1.4%0.0pp	1.4%+0.1pp	1.2%-0.1pp	1.4%+0.1pp	1.2%-0.4pp	1.7%+0.5pp	1.2%
Debt-to-Equity	0.880.0x	0.90+0.1x	0.830.0x	0.800.0x	0.81-0.1x	0.940.0x	0.90-0.1x	0.99
FCF Margin	N/A	-48.6%+22.8pp	-71.4%	N/A	N/A	-43.3%+18.8pp	-62.1%	N/A

Not reported in any period shown, so not listed: Gross Margin, Current Ratio.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.

Similar Companies

Sabra Health Care Reit Inc SBRA

$5.2B

Medical Prop MPW

$3.0B

AMERICAN HEALTHCARE REIT INC AHR

$10.5B

Healthcare Tr Amer Inc HR

$6.6B

Caretrust CTRE

$9.2B

Where National Health Investors Ranks

Frequently Asked Questions

What is National Health Investors's annual revenue?

National Health Investors (NHI) reported $375.6M in total revenue for fiscal year 2025. This represents a 12.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is National Health Investors's revenue growing?

National Health Investors (NHI) revenue grew by 12.1% year-over-year, from $335.2M to $375.6M in fiscal year 2025.

Is National Health Investors profitable?

Yes, National Health Investors (NHI) reported a net income of $142.2M in fiscal year 2025, with a net profit margin of 37.9%.

What is National Health Investors's net profit margin?

National Health Investors (NHI) had a net profit margin of 37.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does National Health Investors pay dividends?

Yes, National Health Investors (NHI) paid $3.64 per share in dividends during fiscal year 2025.

What is National Health Investors's return on equity (ROE)?

National Health Investors (NHI) has a return on equity of 9.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is National Health Investors's free cash flow?

National Health Investors (NHI) recorded an outflow of $57.5M in free cash flow during fiscal year 2025. This represents a -215.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is National Health Investors's operating cash flow?

National Health Investors (NHI) generated $236.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are National Health Investors's total assets?

National Health Investors (NHI) had $2.8B in total assets as of fiscal year 2025, including both current and long-term assets.

What are National Health Investors's capital expenditures?

National Health Investors (NHI) invested $294.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does National Health Investors have outstanding?

National Health Investors (NHI) had 48M shares outstanding as of fiscal year 2025.

What is National Health Investors's debt-to-equity ratio?

National Health Investors (NHI) had a debt-to-equity ratio of 0.83 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is National Health Investors's return on assets (ROA)?

National Health Investors (NHI) had a return on assets of 5.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is National Health Investors's Piotroski F-Score?

National Health Investors (NHI) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are National Health Investors's earnings high quality?

National Health Investors (NHI) has an earnings quality ratio of 1.66x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is National Health Investors?

National Health Investors (NHI) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its REITs peer group. The score is a 0-100 composite of six dimensions (FFO Margin, FFO Growth, Leverage, Interest Cov., AFFO Margin, Dividend Cov.), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.